High Tacrolimus Intra‐Patient Variability and Adverse Outcomes in Cardiac Transplant Recipients: A Single‐Center Study in China
Clinical Transplantation · 2026
DOI: 10.1111/ctr.70427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2026. Verfasst von Zhenzhen Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency and Critical Care Medicine, The Seventh People's Hospital of Zhengzhou, Zhengzhou, China. Hauptthemen laut MEDLINE: Tacrolimus, Heart Transplantation, Immunosuppressive Agents, Graft Rejection. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Project of Zhengzhou Medical and Health Science and Technology Innovation Awareness Plan, Joint Project of Henan Medical Science and Technology Research Program.
Abstract (Originalsprache)
Purpose
To evaluate the association between tacrolimus intra‐patient variability (IPV) and the prognosis of cardiac transplant recipients.
Methods
Tacrolimus trough concentrations (C 0 ) from cardiac transplant recipients were collected during the postoperative months 3–6. Dose‐adjusted IPV values were calculated, and recipients were divided into high‐IPV and low‐IPV groups. The composite endpoint was defined as the occurrence of any one of the following: infection, rejection, or mortality.
Results
A total of 202 recipients were included. The incidence of infections was significantly higher in the high‐IPV group (34.8% vs. 21.1%, χ 2 = 4.480, p = 0.034). The risk of infection and composite endpoint occurrence was approximately 2.2 and 2.1 times higher, respectively, in the high‐IPV group than in the low‐IPV group, with hazard ratios (HR) and 95% CIs of 2.215 (1.175–3.842) and 2.061 (1.258–3.378). No significant differences were observed between the two groups in terms of rejection or mortality ( p > 0.05). Cox regression analysis revealed that the relative risk of composite endpoint occurrence in the high‐IPV group was 2.024 times higher than in the low‐IPV group. The cumulative event‐free survival rates for the composite endpoint differed significantly between the two groups. Log‐rank testing of the survival curves yielded p = 0.004 and HR = 2.061 (95% CI: 1.258–3.378).
Conclusion
Cardiac transplant recipients with high tacrolimus IPV may be at increased risk of adverse events such as infections. Tacrolimus IPV, which is simple to calculate, can serve as a useful follow‐up tool for predicting postoperative adverse outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency and Critical Care Medicine, The Seventh People's Hospital of Zhengzhou, Zhengzhou, China.
- Department of Heart Transplantation Center, The Seventh People's Hospital of Zhengzhou, Zhengzhou, China.
ORCID-Profile: Lin Guo
Förderung
- Project of Zhengzhou Medical and Health Science and Technology Innovation Awareness Plan
- Joint Project of Henan Medical Science and Technology Research Program
Zitieren
APA
Wang, Z., Zheng, H., Zhang, M., Wang, Y., Liu, Y., Zeng, D., Zheng, H., Yang, B., & Guo, L. (2026). High Tacrolimus Intra‐Patient Variability and Adverse Outcomes in Cardiac Transplant Recipients: A Single‐Center Study in China. Clinical Transplantation. https://doi.org/10.1111/ctr.70427
Vancouver
Wang Z, Zheng H, Zhang M, Wang Y, Liu Y, Zeng D, et al. High Tacrolimus Intra‐Patient Variability and Adverse Outcomes in Cardiac Transplant Recipients: A Single‐Center Study in China. Clinical Transplantation. 2026. doi:10.1111/ctr.70427
BibTeX
@article{Wang2026,
author = {Wang, Zhenzhen and Zheng, Hua and Zhang, Mian and Wang, Yibo and Liu, Yunfei and Zeng, Dong and Zheng, Hongxiang and Yang, Bin and Guo, Lin},
title = {High Tacrolimus Intra‐Patient Variability and Adverse Outcomes in Cardiac Transplant Recipients: A Single‐Center Study in China},
journal = {Clinical Transplantation},
year = {2026},
doi = {10.1111/ctr.70427}
}
EUVIMED